The Trump administration shared on Tuesday the outlines of the way it plans to push pharmaceutical firms to decrease their U.S. drug costs to convey them extra in step with different nations, kicking off high-stakes negotiations with the businesses.
The Division of Well being and Human Companies will intention to barter drug costs all the way down to the bottom costs paid by peer nations, and the pricing targets will apply to brand-name medicine that don’t face competitors from generics or biosimilars.
“We anticipate pharmaceutical producers to satisfy their dedication to decrease costs for American sufferers, or we’ll take motion to make sure they do,” HHS Secretary Robert F. Kennedy Jr. stated in a press release.
This text is unique to STAT+ subscribers
Unlock this text — plus each day protection and evaluation of the biotech sector — by subscribing to STAT+.
Have already got an account? Log in
To learn the remainder of this story subscribe to STAT+.
